微小RNA与胃癌的关系

微小RNA（microRNA、miRNA）与胃癌的发生发展可通过调控其靶基因参与的信号传导通路，影响胃癌的发生、侵袭和转移等过程，发挥着类似于癌基因或抑癌基因的作用。目前，已发现多种microR—NA与胃癌关系密切，包括通过调节周期蛋白依赖性蛋白激酶（Cdk）表达影响胃癌细胞增殖的miR-106b-93～25家族、miR-222—221家族和抑制高迁移率族蛋白A2（HMGA2）基因表达抑制胃癌细胞转移的miR-129和let-一7miRNA家族等。另有研究表明，miR-d21和miR-31检测阳性率显著高于血清CEA，可能成为新的胃癌肿瘤标志物。miR-15b和miR-16与胃癌多药耐药的关系也说明microRNA可能成为胃癌治疗新的靶点。

MicroRNA Expression and Gastric Cancer

MicroRNAs （miRNAs） have been indicated to play important roles in gastric cancer. miRNAs can act as oncogene or anti-oncogene to control individual development, proliferation, differentiation and cell apoptosis by regulating their targeted gene-related signal pathways. Several microRNAs have been found to have close correlations with gastric cancer, such as miR-106b -93 ~ 25 clusters, miR-222 -221 clusters and miR-129 which could result in activation or suppression of Cdk2 and let-7 microRNA family which negatively regulate HMGA2. The finding that miR-421 and miR-31 are significantly overexpressed in gastric cancer suggests that miR-421 and miR-31 may be used as potential diagnostic biomarkers of gastric cancer. MiR-15 and miR-16 are also found to modulate muhidrug resistance in gastric cancer. Hence, miRNAs might be novel targets for development of therapeutics in gastric cancer.